␣-Synuclein has been identified as a major component of Lewy body inclusions, which are one of the pathologic hallmarks of idiopathic Parkinson's disease. Mutations in ␣-synuclein have been found to be responsible for rare familial cases of Parkinsonism. To test whether overexpression of human ␣-synuclein leads to inclusion formation and neuronal loss of dopaminergic cells in the substantia nigra, we made transgenic mice in which the expression of wild-type or mutant (A30P and A53T) human ␣-synuclein protein was driven by the promoter from the tyrosine hydroxylase gene. Even though high levels of human ␣-synuclein accumulated in dopaminergic cell bodies, Lewy-typepositive inclusions did not develop in the nigrostriatal system. In addition, the number of nigral neurons and the levels of striatal dopamine were unchanged relative to non-transgenic littermates, in mice up to one year of age. These findings suggest that overexpression of ␣-synuclein within nigrostriatal dopaminergic neurons is not in itself sufficient to cause aggregation into Lewy body-like inclusions, nor does it trigger overt neurodegenerative changes.
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INTRODUCTION
The potential role of ␣-synuclein in the pathophysiology of Parkinson's disease has attracted a great deal of attention as mutations in the ␣-synuclein gene have been found to be responsible for rare, familial cases of Parkinsonism (Polymeropoulos et al., 1997; Kruger et al., 1998) . Abnormal ␣-synuclein has been identified as a major component of Lewy bodies, one of the pathologic hallmarks of Parkinson's disease (Spillantini et al., 1998) . Lewy body inclusions are prominent in neurons of the substantia nigra and in addition to ␣-synuclein fibrils, they also include ubiquitin, neurofilaments, and a range of other proteins (reviewed in Braak and Braak, 2000) . In a recent study, mice expressing a wild-type (wt) human ␣-synuclein transgene driven by the platelet-derived growth factor (PDGF) promoter were reported to develop ␣-synuclein and ubiquitin immunoreactive inclusions that were argyrophilic and positive for thioflavin S. Although nigral cell body numbers were normal, there was evidence of damage to striatal dopaminergic ter-
